Michael F Berger

Rapid analysis of the DNA-binding specificities of transcription factors with DNA microarrays.

Protein binding microarrays (PBMs) for rapid, high-throughput characterization of the sequence specificities of DNA binding proteins.

Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities.

Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae.

Inferring condition-specific transcription factor function from DNA binding and gene expression data.

Microarray analyses of newborn mouse ovaries lacking Nobox.

Variation in homeodomain DNA binding revealed by high-resolution analysis of sequence preferences.

Design of compact, universal DNA microarrays for protein binding microarray experiments.

The Vibrio harveyi master quorum-sensing regulator, LuxR, a TetR-type protein is both an activator and a repressor: DNA recognition and binding specificity at target promoters.

Predicting the binding preference of transcription factors to individual DNA k-mers.

Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells.

High-resolution DNA-binding specificity analysis of yeast transcription factors.

Universal protein-binding microarrays for the comprehensive characterization of the DNA-binding specificities of transcription factors.

Diversity and complexity in DNA recognition by transcription factors.

Applications of genomics in melanoma oncogene discovery.

Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts.

Conservation and regulatory associations of a wide affinity range of mouse transcription factor binding sites.

Integrative analysis of the melanoma transcriptome.

Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo.

Objective sequence-based subfamily classifications of mouse homeodomains reflect their in vitro DNA-binding preferences.

Notch and MAML-1 complexation do not detectably alter the DNA binding specificity of the transcription factor CSL.

The genomic complexity of primary human prostate cancer.

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

The mutational landscape of head and neck squamous cell carcinoma.

Molecular mechanism underlying the regulatory specificity of a Drosophila homeodomain protein that specifies myoblast identity.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

Melanoma genome sequencing reveals frequent PREX2 mutations.

Genome sequencing identifies a basis for everolimus sensitivity.

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Punctuated evolution of prostate cancer genomes.